BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 16354907)

  • 21. Endothelial LRP1 transports amyloid-β(1-42) across the blood-brain barrier.
    Storck SE; Meister S; Nahrath J; Meißner JN; Schubert N; Di Spiezio A; Baches S; Vandenbroucke RE; Bouter Y; Prikulis I; Korth C; Weggen S; Heimann A; Schwaninger M; Bayer TA; Pietrzik CU
    J Clin Invest; 2016 Jan; 126(1):123-36. PubMed ID: 26619118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fusion of hIgG1-Fc to 111In-anti-amyloid single domain antibody fragment VHH-pa2H prolongs blood residential time in APP/PS1 mice but does not increase brain uptake.
    Rotman M; Welling MM; van den Boogaard ML; Moursel LG; van der Graaf LM; van Buchem MA; van der Maarel SM; van der Weerd L
    Nucl Med Biol; 2015 Aug; 42(8):695-702. PubMed ID: 25960433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier.
    Bachmeier C; Paris D; Beaulieu-Abdelahad D; Mouzon B; Mullan M; Crawford F
    Neurodegener Dis; 2013; 11(1):13-21. PubMed ID: 22572854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides.
    Xiong H; Callaghan D; Jones A; Bai J; Rasquinha I; Smith C; Pei K; Walker D; Lue LF; Stanimirovic D; Zhang W
    J Neurosci; 2009 Apr; 29(17):5463-75. PubMed ID: 19403814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-malaria drug artesunate prevents development of amyloid-β pathology in mice by upregulating PICALM at the blood-brain barrier.
    Kisler K; Sagare AP; Lazic D; Bazzi S; Lawson E; Hsu CJ; Wang Y; Ramanathan A; Nelson AR; Zhao Z; Zlokovic BV
    Mol Neurodegener; 2023 Jan; 18(1):7. PubMed ID: 36707892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic cerebral hypoperfusion-induced impairment of Aβ clearance requires HB-EGF-dependent sequential activation of HIF1α and MMP9.
    Ashok A; Rai NK; Raza W; Pandey R; Bandyopadhyay S
    Neurobiol Dis; 2016 Nov; 95():179-93. PubMed ID: 27431094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A lipoprotein receptor cluster IV mutant preferentially binds amyloid-β and regulates its clearance from the mouse brain.
    Sagare AP; Bell RD; Srivastava A; Sengillo JD; Singh I; Nishida Y; Chow N; Zlokovic BV
    J Biol Chem; 2013 May; 288(21):15154-66. PubMed ID: 23580652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier.
    Bachmeier C; Beaulieu-Abdelahad D; Mullan M; Paris D
    Mol Cell Neurosci; 2013 Sep; 56():255-62. PubMed ID: 23831388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.
    Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Poduslo JF
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1370-8. PubMed ID: 15743932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipopolysaccharide impairs amyloid β efflux from brain: altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood-brain barrier.
    Erickson MA; Hartvigson PE; Morofuji Y; Owen JB; Butterfield DA; Banks WA
    J Neuroinflammation; 2012 Jun; 9():150. PubMed ID: 22747709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice.
    Abdallah IM; Al-Shami KM; Yang E; Kaddoumi A
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased efflux of amyloid-β peptides through the blood-brain barrier by muscarinic acetylcholine receptor inhibition reduces pathological phenotypes in mouse models of brain amyloidosis.
    Paganetti P; Antoniello K; Devraj K; Toni N; Kieran D; Madani R; Pihlgren M; Adolfsson O; Froestl W; Schrattenholz A; Liebner S; Havas D; Windisch M; Cirrito JR; Pfeifer A; Muhs A
    J Alzheimers Dis; 2014; 38(4):767-86. PubMed ID: 24072071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy.
    Finke JM; Banks WA
    Hum Antibodies; 2017; 25(3-4):131-146. PubMed ID: 28035915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omega-3 polyunsaturated fatty acids promote brain-to-blood clearance of β-Amyloid in a mouse model with Alzheimer's disease.
    Yan L; Xie Y; Satyanarayanan SK; Zeng H; Liu Q; Huang M; Ma Y; Wan JB; Yao X; Su KP; Su H
    Brain Behav Immun; 2020 Mar; 85():35-45. PubMed ID: 31132459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1,25-Dihydroxyvitamin D3 regulates expression of LRP1 and RAGE in vitro and in vivo, enhancing Aβ1-40 brain-to-blood efflux and peripheral uptake transport.
    Guo YX; He LY; Zhang M; Wang F; Liu F; Peng WX
    Neuroscience; 2016 May; 322():28-38. PubMed ID: 26820600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.
    LaRue B; Hogg E; Sagare A; Jovanovic S; Maness L; Maurer C; Deane R; Zlokovic BV
    J Neurosci Methods; 2004 Sep; 138(1-2):233-42. PubMed ID: 15325132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease.
    Deane R; Sagare A; Zlokovic BV
    Curr Pharm Des; 2008; 14(16):1601-5. PubMed ID: 18673201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition.
    Jaeger LB; Dohgu S; Hwang MC; Farr SA; Murphy MP; Fleegal-DeMotta MA; Lynch JL; Robinson SM; Niehoff ML; Johnson SN; Kumar VB; Banks WA
    J Alzheimers Dis; 2009; 17(3):553-70. PubMed ID: 19433890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amyloid-Beta Peptides 40 and 42 Employ Distinct Molecular Pathways for Cell Entry and Intracellular Transit at the Blood-Brain Barrier Endothelium.
    Wang Z; Sharda N; Omtri RS; Li L; Kandimalla KK
    Mol Pharmacol; 2023 Nov; 104(5):203-213. PubMed ID: 37541759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparanase overexpression impedes perivascular clearance of amyloid-β from murine brain: relevance to Alzheimer's disease.
    Zhang X; O'Callaghan P; Li H; Tan Y; Zhang G; Barash U; Wang X; Lannfelt L; Vlodavsky I; Lindahl U; Li JP
    Acta Neuropathol Commun; 2021 May; 9(1):84. PubMed ID: 33971986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.